Trials Sponsors Conditions Drugs Pricing

Conditions

Bladder Cancer Carcinoma, Non-Small-Cell Lung Mesothelioma Ovarian Cancer Peritoneal Cancer Thymoma Thymus Cancer Uterine Cervical Cancer

Outcome Measures

Primary Outcomes (2)

Dose-limiting toxicity of the combination of bosutinib and pemetrexed
CTCAE Grade 3 or 4 non-hematologic toxicities other than alopecia, nausea and vomiting.
21 days
Maximum tolerated dose of the combination of bosutinib and pemetrexed
completion of dose escalation

Secondary Outcomes (3)

Adverse events of the combination of bosutinib and pemetrexed
16 weeks

Study Arms (1)

Bosutinib and Pemetrexed

EXPERIMENTAL

Bosutinib and pemetrexed

Drug: BosutinibDrug: Pemetrexed

Interventions

BosutinibDrug

100mg daily for 4 cycles (21 days per cycle)

Bosutinib and Pemetrexed

PemetrexedDrug

500 mg/m2 every 21 days for 4 cycles

Bosutinib and Pemetrexed

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Pathologically or cytologically proven advanced, metastatic non-squamous non-small cell lung cancer, pleural malignant mesothelioma, bladder or urethral cancer, ovarian cancer, primary peritoneal cancer, thymoma and thymic cancer and uterine cervical cancer.
Measurable disease

Sponsors & Collaborators

Nagla Abdel Karim
Otherlead

Study Sites (1)

Augusta University Georgia Cancer Center

Augusta, Georgia, 30912, United States

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell LungMesotheliomaUrinary Bladder NeoplasmsOvarian NeoplasmsThymomaThymus NeoplasmsUterine Cervical Neoplasms

Interventions

bosutinibPemetrexed

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic Neoplasms

Study Officials

Nagla Karim, MD
Augusta University Georgia Cancer Center
PRINCIPAL INVESTIGATOR

Enrollment

6 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR INVESTIGATOR
PI Title: Associate Professor of Medicine

Study Record Dates

First Submitted

January 13, 2017

First Posted

January 18, 2017

Study Start

December 10, 2019

Actual (reported)

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (3)

Study Arms (1)

Bosutinib and Pemetrexed

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (3)

Study Arms (1)

Bosutinib and Pemetrexed

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record

Locations